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Abstract
Introduction: The World Health Organization (WHO) 2010 guidelines recommended to treat all HIV-infected children less than
two years of age. We described the inclusion process and its correlates of HIV-infected children initiated on early antiretroviral
therapy (EART) at less than two years of age in Abidjan, Coˆte d’Ivoire, and Ouagadougou, Burkina Faso.
Methods: All children with HIV-1 infection confirmed with a DNA PCR test of a blood sample, aged less than two years, living at a
distance less than two hours from the centres and whose parents (or mother if she was the only legal guardian or the legal
caregiver if parents were not alive) agreed to participate in the MONOD ANRS 12206 project were included in a cohort to receive
EART based on lopinavir/r. We used logistic regression to identify correlates of inclusion.
Results: Among the 217 children screened and referred to the MONOD centres, 161 (74%) were included and initiated on EART.
The main reasons of non-inclusion were fear of father’s refusal (48%), mortality (24%), false-positive HIV infection test (16%) and
other ineligibility reasons (12%). Having previously disclosed the child’s and mother’s HIV status to the father (adjusted odds
ratio (aOR): 3.20; 95% confidence interval (95% CI): 1.55 to 6.69) and being older than 12 months (aOR: 2.05; 95% CI: 1.02 to
4.12) were correlates of EART initiation. At EART initiation, the median age was 13.5 months, 70% had reached WHO Stage
3/4 and 57% had a severe immune deficiency.
Conclusions: Fear of stigmatization by the father and early competing mortality were the major reasons for missed opportunities
of EART initiation. There is an urgent need to involve fathers in the care of their HIV-exposed children and to promote early
infant diagnosis to improve their future access to EART and survival.
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Introduction
The paediatric epidemic of HIV remains a major concern in the
world. In 2012, three million children were living with HIV in-
fection worldwide, 91% of whom were in sub-Saharan Africa [1].
Despite a decrease in HIV prevalence among pregnant
women over the last decade, the epidemic is still widespread
in Burkina Faso (1.7% prevalence in 2011 [2]) and in Coˆte
d’Ivoire (4.5% prevalence in 2009 [3]). Although the coverage
of prevention of mother-to-child transmission (PMTCT)
programmes has improved in both countries, it still remains
insufficient. In 2011, 67% and 29% of HIV-positive women
received the PMTCT intervention in Burkina Faso [2] and
Coˆte d’Ivoire [4], respectively, with a growing HIV paediatric
epidemic. In the absence of any intervention, the mortality of
HIV-infected children remains high, reaching 50% at the age of
two [5].
In 2008, the antiretroviral CHER trial demonstrated the
efficacy of starting early antiretroviral therapy (EART) before
two months of age in reducing infant mortality in HIV-
infected infants compared with those treated according to
the World Health Organization (WHO) 2006 recommenda-
tions: 4% versus 16% respectively [6]. Since then, the WHO
has recommended the initiation of EART in all HIV-infected
children before the age of 12 months, regardless of their
disease progression [7], extended up to 24 months of age in
2010 [8]. Consequently, a systematic early infant diagnosis of
HIV was recommended for all HIV-exposed children from the
age of six weeks [8] in order to initiate EART in those infected
by HIV.
However, access to EART for HIV-infected children is
complex in the African context as operational issues further
complicate the situation. Overall, access to antiretroviral
therapy (ART) has significantly improved, but remains
insufficient, with only 34% of eligible children in sub-Saharan
Africa having access to treatment in 2012, compared to 64%
of adults [1]. First, access to early infant diagnosis under the
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age of 18 months requires sophisticated PCR techniques due
to the persistence of maternal antibodies in the child’s blood.
These techniques are not available everywhere [9]. Second
among the barriers, the lack of service delivery and low
acceptability by healthcare workers and the community are
frequent [1012]. Consequently, providing a continuum of
care for HIV-exposed children remains challenging. Those
HIV-infected children who have a chance to access ART are
frequently treated late, at an advanced age (median age
greater than five years) and at an advanced stage of the
disease [13,14].
Since the promulgation of the WHO 2010 recommenda-
tions, no study has assessed the missed opportunities of the
pre-EART cascade beyond HIV diagnosis and the acceptability
of EART proposed in HIV-infected children less than two years
old in West Africa. We studied the inclusion process and the
family acceptability of EART as part of the pre-ART cascade
and its correlates among HIV-infected children less than two
years old in Abidjan and Ouagadougou through the descrip-
tion of the inclusion process in the therapeutic cohort of the
MONOD ANRS 12206 project.
Methods
Settings
The MONOD ANRS 12206 project was funded by the French
National Agency for Research on AIDS and Viral Hepatitis
(ANRS), the European and Developing Countries Trials
Partnership (EDCTP) and the Luxembourg Institute of Health.
This was a multicentre project launched in two West African
countries (Burkina Faso and Coˆte d’Ivoire) targeted at EART
implementation before the age of two as recommended by
the WHO in 2010. This project was conducted in the two
paediatric wards of the Yalgado Oue´draogo and Charles de
Gaulle University Hospitals in Ouagadougou, Burkina Faso,
and in two public paediatric HIV programme sites (FSU
Abobo-Avocatier, CEPREF-Yopougon) as well as in the two
paediatric wards of the Yopougon and Cocody University
Hospitals in Abidjan, Coˆte d’Ivoire.
Study design
We studied the inclusion process of children screened to be
enrolled in the MONOD ANRS 12206 project until their
confirmed inclusion with EART initiation. Eligible children
were initially included in a 12-month therapeutic prospective
cohort with a twice-daily EART combination (zidovudine (AZT)
or abacavir (ABC))lamivudine (3TC)lopinavir/ritonavir
(LPV/r) in addition to cotrimoxazole prophylaxis and ther-
apeutic education (teaching the caregiver how to comply
with the daily dosages and hours of treatment).
Participants
All HIV-1-infected children screened by HIV DNA PCR on dried
blood spot samples under the umbrella of the national
screening programme in urban centres, less than two years
old and ART-naive except for PMTCT prophylaxis of HIV were
referred with their parents (or the legal caregiver if parents
were not alive) to one of the MONOD healthcare facilities in
Abidjan and Ouagadougou to be pre-included. Those children
with HIV infection confirmed by DNA PCR on blood sample,
with haemoglobin levels greater than 7 g/dl; neutrophils
greater than 750/mm3; creatinine five times below the
normal threshold; aspartate aminotransferase (AST) and
alanine-amino-transferase (ALT) five times below the normal
threshold and whose parents (or mother if she was the only
legal guardian, or the legal caregiver if parents were not
alive) consented to participation in the MONOD ANRS 12206
project, were initiated on EART. Children diagnosed with
tuberculosis at pre-inclusion were included in a separate
cohort and received an efavirenz (EFV)-based therapy be-
cause of the drug interaction between LPV/r and tuberculosis
treatment [15].
Data collection
Patients’ data were collected prospectively using standar-
dized questionnaires at their first contact, pre-inclusion and
inclusion visits. The socio-demographic data of mothers and
children and PMTCT exposure data were collected at the first
contact visit. After obtaining the parents’ written informed
consent to participate in the project, all socio-demographic
data, data related to the father’s HIV status, DNA PCR to
confirm the child’s HIV status, haematology, biochemistry,
CD4 percentage and viral load data of the children were
collected at the pre-inclusion visit (four weeks before
inclusion). At the inclusion visit, children’s anthropometric
and clinical data were collected. Clinical stage and immuno-
deficiency were defined according to the WHO recommenda-
tions issued in 2006 [16].
Statistical analysis
We described the pre-ART inclusion process of children
initially diagnosed as HIV infected and the causes of non-
inclusion. We described the socio-demographic characteris-
tics of the children at their first contact and pre-inclusion
visits according to their inclusion in the EART therapeutic
cohort. For children with a confirmed HIV infection status, we
analyzed the correlates of inclusion in the therapeutic cohort,
using a multivariate logistic regression including all uncorre-
lated variables associated in the univariate analysis with
pB0.25. Then, we conducted a stepwise descending ad-
justed analysis.
Baseline categorical data are presented as frequencies
(percentage), whereas continuous variables are presented
using the mean and standard deviation (SD) for normally
distributed continuous data or using median and interquar-
tile ranges (IQR) for non-normally distributed continuous
data. We compared categorical data using the chi-square
test or Fisher’s exact test, and we used Student’s t-test or
Wilcoxon rank-sum test to compare continuous data.
Weight-for-height, weight-for-age and height-for-age were
used to assess children’s nutritional status. Each outcome
was standardized (z-score) for age and gender using the WHO
growth standards [17]. We defined underweight at baseline
as weight-for-age z-score (WAZ) B2 SD and stunting as
height-for-age z-score (HAZ) B2 SD.
All statistical analyses were performed with SAS 9.3 (SAS
Institute Inc., Cary, NC, USA) except for anthropometric
indicators, which were analyzed with ENA/Epi Info 3.5.1.
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Ethical considerations
Both parents (or the mother if she was the only legal
guardian, or the legal caregiver if parents were not alive) of
each child enrolled gave their written informed consent to
participate in the MONOD ANRS 12206 project, which was
approved by both national ethics committees of Burkina Faso
and Coˆte d’Ivoire. The consent had to be signed no later than
the pre-inclusion visit.
Results
Cohort profile
From May 2011 to February 2013, 217 children had a first
contact visit, and of these 161 were included in the MONOD
cohort (156 in the initial cohort and 5 in the tuberculosis
cohort). The cumulative rate of inclusion was 74%. The main
reasons for non-inclusion (N56) were linked to the refusal
of EART for the child by the father or father’s denial of child’s
HIV status (27/56; 48%), early mortality (13/56; 24%), child
found to be HIV negative on retested sample (9/56; 16%)
and ineligibility for geographical reasons or due to severe
disorders of baseline blood haematology/chemistry (7/56;
12%). Thus, among the 208 HIV-infected children confirmed
eligible for treatment, 77% were initiated on EART (95%
confidence interval (95% CI): 71% to 83%) (Figure 1).
Characteristics of eligible children according to their
inclusion in the EART therapeutic cohort (N208)
Table 1 provides the baseline characteristics of the children
according to their inclusion in the MONOD cohort. Overall,
the median age at first HIV diagnosis and at the first contact
visit were 8.4 months (IQR: 2.9 to 15.6) and 11.7 months
(IQR: 6.0 to 17.3), respectively; 54% were girls. According to
inclusion in the MONOD cohort, there was no difference in
median age at first contact. However, median age at first HIV
diagnosis was significantly different between those included
and non-included children (p0.03): children included were
three months older at first HIV diagnosis than those not
included. At the first contact visit, children were most
often accompanied by both parents (56.7%); this proportion
was significantly higher in children included (pB0.01). The
mothers of the children included were more often single
mothers compared to those of children not included
(p0.02). Overall, 62% of fathers had already been informed
of the HIV status of their own child and of the mother; this
proportion was significantly higher in children included
(pB0.01).
Correlates of inclusion were investigated in a multivariate
analysis (Table 2). Children who were accompanied by both
parents at the first contact visit were 10 times more likely to
be included and initiated on EART. In the final adjusted
analysis, we found that children were more likely to be
included when they were older than 12 months at the first
contact visit (adjusted odds ratio (aOR): 2.05; 95% CI: 1.02 to
4.12) and when the father was informed about the HIV status
of both the mother and the child (aOR: 3.20; 95% CI: 1.55 to
6.69) (Table 2).
Baseline variables of children included according to
study sites
The baseline characteristics of the 161 children included in
the MONOD cohort are described in Table 3 according to
their study site. The median age at ART initiation of children
enrolled was 13.7 months (IQR: 7.7 to 18.4). This age was
significantly different between the two study sites (p0.03):
children in Ouagadougou were two months older than those
in Abidjan. The children were female (54%) and lived with
both parents (67%) regardless of the study sites. Overall, the
First contacts: N = 217
(Abidjan: n = 135, Ouagadougou: n = 82)
Pre-inclusions: N = 183
(Abidjan: n = 114, Ouagadougou: n = 69)
Inclusions: N = 161
(Abidjan: n = 103, Ouagadougou: n = 58)
•    4 deaths
•    21 refusal linked to the father
•    4 fathers not found
•    1 trisomic child
•    1 transfer out to initiate immediate 
     ART
•    3 not eligible (1 HIV not confirmed, 2 
     place of residence not compatible 
     with the follow-up)
•    9 deaths
•    2 parents refusal
•    3 not eligible (1 age > 24 months, 2 
     blood hematology/chemistry 
     disorders)
•    8 HIV-negative on retesting
N = 34
N = 22
Tuberculosis cohort: N = 5
(Abidjan: n = 4, Ouagadougou: n = 1)
Initial cohort: N = 156
(Abidjan: n = 99, Ouagadougou: n = 57)
Figure 1. Cohort profile ofthe ANRS 12206 MONOD study, Abidjan, Ouagadougou, May 2011 to February 2013.
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main caregivers were mothers (83%). However, more fathers
in Ouagadougou (26%) than in Abidjan (1%) were the main
caregivers (p0.01). In Abidjan, parents were significantly
more likely to have access to tap water, electricity and
refrigerators at home compared to those in Ouagadougou.
Over half (51%) of the mothers did not receive any prenatal
PMTCT intervention, and only 35% had ongoing ART at
the time of inclusion of their child. Over half (51%) of the
children included had not received any postnatal prophylaxis
for PMTCT. Self-reported father’s HIV test was unknown for
14% of the children. Only 64% of the fathers reported having
taken an HIV test, but this proportion was significantly higher
in Abidjan than in Ouagadougou: 68% versus 57%, respec-
tively (p0.02). Among the fathers who underwent screen-
ing for HIV infection, 40% reported being HIV positive, of
whom 51% were on ART.
At the initiation of ART, 62% of the children had already
reached a WHO clinical Stage 3 or 4: this proportion was
significantly higher in Ouagadougou than in Abidjan, 88%
versus 48%, respectively (pB0.01). The median percentage
Table 1. Characteristics of eligible children according to their inclusion in the ANRS 12206 MONOD study, Abidjan, Ouagadougou,
May 2011 to February 2013
Total
n208
Not included
n47
Included
n161
Characteristics n (%) n (%) n (%) p
Median child’s age (in months) at first contact (IQR) 11.9 (6.4 to 17.3) 9.5 (5.7 to 17.0) 12.9 (6.6 to 17.3) 0.17*
Child’s age at first contact (in months) 0.08
B12 105 (50.5) 29 (61.7) 76 (47.2)
]12 103 (49.5) 18 (38.3) 85 (52.8)
Median child’s age (in months) at first HIV diagnosis (IQR) 8.4 (2.9 to 15.6) 5.9 (2.4 to 13.0) 9.0 (3.4 to 16.0) 0.03*
Age at first HIV diagnosis (in months) 0.07
B2 29 (14.1) 10 (22.2) 19 (11.8)
]2 177 (85.9) 35 (77.8) 142 (88.2)
Gender 0.87
Male 95 (45.7) 21 (44.7) 74 (46.0)
Female 113 (54.3) 26 (55.3) 87 (54.0)
Vital status of the father B0.01
Alive 146 (70.2) 11 (23.4) 135 (83.8)
Deceased 10 (4.8) 1 (2.1) 9 (5.6)
Unknown/missing 52 (25.0) 35 (74.5) 17 (10.6)
Person accompanying child at the first contact B0.01**
Mother alone 80 (38.5) 38 (80.8) 42 (26.1)
Father alone 3 (1.4) 0 (0.0) 3 (1.9)
Both parents 118 (56.7) 8 (17.0) 110 (68.4)
Legal guardian 2 (1.0) 0 (0.0) 2 (1.2)
Other 5 (2.4) 1 (2.2) 4 (2.4)
Mother still in touch with the child’s father 0.02**
Yes 175 (84.1) 46 (97.9) 129 (80.1)
No 19 (9.1) 0 (0.0) 19 (11.8)
Deceased 10 (4.8) 1 (1.8) 9 (5.6)
Unknown 4 (2.0) 0 (2.1) 4 (2.5)
Father informed of the mother’s HIV status (N198***) B0.01
Yes 124 (62.6) 20 (43.5) 104 (68.4)
No 66 (33.3) 25 (54.3) 41 (27.0)
Unknown 8 (4.1) 1 (2.2) 7 (4.6)
Father informed of his child’s HIV status (N198***) B0.01**
Yes 123 (62.1) 20 (43.5) 103 (67.8)
No 74 (37.4) 26 (56.5) 48 (31.5)
Unknown 1 (0.51) 0 (2.1) 1 (0.7)
IQR: interquartile range; *p-value from Wilcoxon rank-sum test; **p-value from Fisher’s exact test; ***excluding data for children whose fathers
were deceased.
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of CD4 cells was 20% (IQR: 13.5 to 26.2) and 85% of children
had moderate to severe immune deficiency at baseline.
Children from Ouagadougou had a significantly lower CD4
percentage compared to those in Abidjan (pB0.01). Children
included in Ouagadougou were also significantly more
malnourished than those in Abidjan when considering all
anthropometric indicators, with average weight-for-age,
height-for-age and weight-for-height z-scores being signifi-
cantly lower (pB0.01). The median haemoglobin level was
9.0 grams per decilitre (IQR: 8.2 to 9.9) and 80% of children
had a haemoglobin level B10 grams per decilitre, with a
proportion significantly higher in Ouagadougou than in
Abidjan (pB0.01). The average viral load was 6 log10 (SD:
1.1), children from Ouagadougou having a significantly higher
viral load compared to those in Abidjan (pB0.01) (Table 4).
Discussion
Our study reported, for the first time, pre-EART attrition
during the first 24 months of life in West African settings of
intermediate HIV prevalence and in the context of very low
coverage of early infant diagnosis (29% in Ouagadougou; 16%
in Abidjan). The inclusion rate of children referred after a first
positive DBS was 74%. The reasons for non-inclusion in the
MONOD cohort included refusal of EART due to fear of
stigmatization by the father, early competing infant mortality
and false-positive HIV test on DBS. Good communication
between parents, especially when the mother’s and the
child’s HIV status are disclosed to the father, and being older
than 12 months were two factors associated with a greater
acceptability of EART in this research context. As a result of
the low early infant diagnosis coverage in this context,
children were diagnosed at a late age (median eight months
of age), were referred at a median age of 12 months and
subsequently initiated ART at an advanced age (median
14 months). The majority of the children were malnourished
and started EART at an advanced clinical and immunological
stage. These figures show a significant delay in Ouagadougou
compared to Abidjan. In addition, we reported a limited
access to PMTCT interventions, with more than half of the
children included not having received any PMTCT interven-
tion, despite this being recommended in these settings.
Of the 217 children referred to the MONOD study, 9% were
found to be falsely HIV positive after the confirmatory test
usually required before the initiation of EART. Indeed, the
positive predictive value of this test depends on the pre-
valence of the disease in the tested population. As a result, in
low HIV prevalence settings as in our context, the rate of false
positives remains of concern and fully justifies the need for a
systematic confirmatory test recommended by WHO [18].
According to an HIV transmission rate of 5%, the rate of false-
positive DBS could reach 10.3% [19]. This finding confirms the
need to verify the first HIV positive test result in the setting of
intermediate HIV prevalence, but further highlights the need
for lasting stringent quality control and confirmatory testing.
In African settings, the long delay between the collection of
the initial blood sample and the availability of the results after
a confirmatory test complicates the disclosure of the initial
positive result to the family, as well as the monitoring of the
children over the cascade of care [20]. The problem of false-
positive results can also undermine community trust in the
reliability of early infant diagnosis and lead to possible
diagnosis and EART delays. It also exposes HIV-uninfected
children to the risk of antiretroviral side effects if they are not
identified.
Table 2. Factors associated with inclusion in the ANRS 12206 MONOD study, Abidjan, Ouagadougou, May 2011 to February 2013
(N208)
Unadjusted bivariate analysis Adjusted multivariate analysis
Characteristics OR 95% CI OR 95% CI
Child’s age at first contact (months)
B12 Reference Reference
]12 1.80 0.92 to 3.50 2.05 1.02 to 4.12
Child’s age at first HIV diagnosis (months)
B2 Reference
]2 2.13 0.91 to 4.99
Gender
Male Reference
Female 0.95 0.49 to 1.82
Person accompanying child at the first contact
Mother or legal guardian Reference
Both parents or other 10.24 4.59 to 22.84
Father informed of HIV status of the mother and/or his child
No/unknown Reference Reference
Mother and child 3.04 1.50 to 6.19 3.20 1.55 to 6.59
Mother only 5.18 1.10 to 24.34 6.21 1.29 to 29.78
Child only 3.96 0.82 to 19.04 4.08 0.83 to 19.89
OR: odds ratio; CI: confidence interval.
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Table 3. Baseline socio-demographic characteristics of the 161 HIV-infected children included in the ANRS 12206 MONOD study
according to site (Abidjan, Ouagadougou, May 2011 to February 2013)
Total
n161
Abidjan
n103
Ouagadougou
n58
Characteristics n (%) n (%) n (%) p
Median child’s age (in months) at ART initiation (IQR) 13.6 (7.7 to 18.4) 12.9 (6.7 to 18.3) 14.6 (10.1 to 19.5) 0.03
Child’s age at EART initiation (in months)
B12 70 (43.5) 50 (48.5) 20 (34.5) 0.08
]12 91 (56.5) 53 (51.5) 38 (65.5)
Gender 0.38
Male 74 (46.0) 50 (48.5) 24 (41.4)
Female 87 (54.0) 53 (51.5) 34 (58.1)
Main caregiver B0.01
Mother 133 (82.6) 93 (90.3) 40 (69.0)
Father 16 (9.9) 1 (1.0) 15 (25.8)
Other 12 (7.5) 9 (8.7) 3 (5.2)
Type of housing 0.02
Individual housing 83 (51.5) 46 (44.7) 37 (63.8)
Shared housing 78 (48.5) 57 (55.3) 21 (36.2)
Tap water at home B0.01
Yes 108 (67.1) 87 (84.5) 21 (36.2)
No 53 (32.9) 16 (15.5) 37 (63.8)
Electricity at home B0.01
Yes 120 (74.5) 98 (95.2) 22 (37.9)
No 41 (25.5) 5 (4.8) 36 (62.1)
Fridge at home 0.02
Yes 36 (22.4) 29 (28.2) 7 (12.1)
No 125 (77.6) 74 (71.8) 51 (87.9)
Orphan 0.17
Both parents alive 146 (90.7) 91 (88.4) 55 (94.8)
Mother deceased 6 (3.7) 6 (5.8) 0 (0.0)
Father deceased 9 (5.6) 6 (5.8) 3 (5.2)
Family structure 0.65
Two parents 109 (67.3) 71 (68.9) 38 (65.5)
Single parent/missing 52 (32.1) 32 (31.1) 20 (34.5)
Mother on ART*** 0.06
Yes 56 (34.8) 42 (40.8) 14 (24.1)
No 94 (58.4) 53 (51.4) 41 (70.7)
Unknown 11 (6.8) 8 (7.8) 3 (5.2)
Maternal PMTCT prophylaxis 0.79
Yes 66 (41.0) 41 (39.8) 25 (43.1)
No 83 (51.5) 55 (53.4) 28 (48.3)
Unknown 12 (7.5) 7 (6.8) 5 (8.6)
Postnatal PMTCT prophylaxis 0.93
Yes 66 (41.0) 43 (41.7) 23 (39.7)
No 83 (51.5) 52 (50.5) 31 (53.4)
Unknown 12 (7.5) 8 (7.8) 4 (6.9)
Father tested for HIV 0.03
Yes 103 (64.0) 70 (68.0) 33 (56.9)
No 35 (21.7) 24 (23.3) 11 (19.0)
Unknown 23 (14.3) 9 (8.7) 14 (24.1)
Father HIV positive*** (N103) 0.06**
Yes 41 (39.8) 29 (41.4) 12 (36.4)
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We show that EART is feasible in our context, reaching 77%
of the children with a confirmed HIV diagnosis. However,
despite the referral network set up to capture children eligible
for EART through the MONOD project, the initiation of
antiretroviral treatment was considerably delayed compared
to the CHER strategy, especially in Burkina Faso, cumulating in
delays in the pre-EART cascade (HIV diagnosis, HIV confirma-
tion, EART initiation). The MONOD cohort aimed at initiating
ART as soon as possible after early infant diagnosis (from
12 weeks). However, our findings showed that more than half
of the children started EARTafter their first birthday, with high
competing mortality before the initiation of EART. Children
in Burkina Faso were older at the initiation of EART compared
to those in Coˆte d’Ivoire. This difference between the study
sites can be explained by the fact that there is a closer link
between PMTCT services and postnatal services in Abidjan as
compared to Ouagadougou. One of the healthcare centres of
the MONOD project in Abidjan included a PMTCT project.
Another likely explanation is the fact that the majority
of children in Ouagadougou were recruited from the two
university hospitals while they presented HIV-related symp-
toms, which led the paediatricians to propose an HIV
diagnostic test for them. This late HIV infection testing at a
symptomatic stage of illness has already been described
elsewhere in Ethiopia [21]. Other studies have indicated that
paediatric ART is often started too late, when children are
already advanced in their disease and are immunodeficient
[2227]. This also occurred in the field reality of the MONOD
settings and most likely explained the early high mortality
rate, highlighting the importance of starting ART as early as
possible.
The delay in the initiation of EART is essentially due to the
difficulty of early infant diagnosis, as already observed in
other studies, in low income countries [11,27,28]. This delay
in access to early diagnosis can be explained by the lack of
service delivery, especially because of the insufficient avail-
ability of virological diagnostics, the lack of reagents, the time
required to perform tests, the lack of support services for the
samples’ transportation between healthcare sites and labo-
ratories, the lack of integration of testing within existing
programmes such as immunization programmes, the missed
opportunities to diagnose children in hospital and the low
acceptability of early screening by the community and
healthcare workers [11,12,2932].
In our study, the cumulative rate of EART initiation before
the age of two years reached 77%. Five studies conducted in
Africa and Asia have reported proportions of ART initiation
ranging between 40% and 99% [33]. This variability can be
partly explained by the fact that the studies were performed
at different timing regarding the subsequent recommenda-
tions for antiretroviral treatment initiation. In addition,
these studies have included older children with a median
age ranging between 2.2 and 6.5 years [33]. In our study, we
report that variables related to the quality of communication
within the parental couple regarding maternal and child HIV
status disclosure proved to be important factors to favour an
EART initiation. EART initiation also depends on several socio-
economic factors such as the cost of transportation, avail-
ability of food aid, time constraint, perception of child health,
stigma, beliefs and paternal support [34]. In our study, the
cost of transportation was not considered as an obstacle as
we provided transportation fees to the caregivers. The non-
disclosure of the maternal and the child’s HIV status to the
father was clearly a missed opportunity to initiate EART.
A child’s HIV positive status usually indicates maternal
infection and the resultant anxiety, fear of blame, social
and healthcare discrimination as well as marital abandon-
ment may negatively influence the mother’s acceptance of
the HIV status of the child [35,36]. Braitstein and al. showed
that 30% of children’s caregivers in Kenya reported that the
child was lost-to-follow up because they did not want to
share the child’s HIV status with their partner [37].
We also found that being older than 12 months at the first
contact visit increased the probability of initiation of EART.
This result was likely due to the delay in HIV diagnosis, with
testing often performed late, but also reflects the perception
of the child’s health by the parents. Indeed, parents agreed
more readily to an HIV test and to initiation of therapy
in children who were symptomatic [34]. Over one-third
of children included in our study were already severely
malnourished, with a higher proportion in Ouagadougou than
in Abidjan. The WHO clinical stage and immunodeficiency
Table 3 (Continued )
Total
n161
Abidjan
n103
Ouagadougou
n58
Characteristics n (%) n (%) n (%) p
No 59 (57.3) 41 (58.6) 18 (54.5)
Unknown 3 (2.9) 0 (0.0) 3 (9.1)
Father on ART*** (N41) 0.87**
Yes 21 (51.2) 14 (48.3) 7 (58.3)
No 18 (43.9) 13 (44.8) 5 (41.7)
Unknown 2 (4.9) 2 (6.9) 0 (0.0)
ART: antiretroviral therapy; EART: early ART; PMTCT: prevention of mother-to child transmission; IQR: interquartile range; *p-value from
Wilcoxon rank-sum test; **p-value from Fisher’s exact test; ***self-reported.
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status were also more advanced, consistently reflecting the
recruitment bias in the hospital settings in Ouagadougou
compared to Abidjan.
Our study also highlighted the limited access to PMTCT
intervention in West African settings with an intermediate
HIV prevalence, with more than 50% of children not having
received any PMTCT prophylaxis. This situation is partly due
to the missed opportunities of prenatal HIV testing. PMTCT
interventions are proposed in a context where stigma
remains high and where a significant number of pregnant
Table 4. Baseline clinical, anthropometric, haematological, immunological and virological characteristics of the 161 HIV-infected
children included in the ANRS 12206 MONOD study according to site (Abidjan, Ouagadougou, May 2011 to February 2013)
Total
N161
Abidjan
n103
Ouagadougou
n58
Characteristics n (%) n (%) n (%) p
WHO stage at ART initiation B0.01
1 48 (29.8) 41 (39.8) 7 (12.1)
2 13 (8.1) 13 (12.6) 0 (0.0)
3 63 (39.1) 34 (33.0) 29 (50.0)
4 37 (30.0) 15 (14.6) 22 (37.9)
Weight-for-age z-score
Mean (SD) 2.4 (1.7) 2.0 (1.6) 3.1 (1.5) B0.01
]2 75 (46.6) 61 (59.2) 14 (24.1) B0.01
2, 3 28 (17.4) 13 (12.6) 15 (25.9)
B3 58 (36.0) 29 (28.2) 29 (50.0)
Height-for-age z-score
Mean (SD) 2.3 (1.8) 1.9 (1.9) 2.8 (1.6) B0.01
]2 78 (48.5) 61 (59.2) 17 (29.3) B0.01
2, 3 34 (21.1) 17 (16.5) 17 (29.3)
B3 49 (30.4) 25 (24.3) 24 (41.4)
Weight-for-height z-score
Mean (SD) 1.6 (1.5) 1.3 (1.5) 2.2 (1.5) B0.01
]2 103 (64.0) 77 (74.8) 26 (44.9) B0.01
2, 3 30 (18.6) 15 (14.6) 15 (25.8)
B3 28 (17.4) 11 (10.6) 17 (29.3)
Haemoglobin at initiation (g/dl)
Median (IQR) 9.0 (8.2 to 9.9) 9.2 (8.5 to 10.0) 8.4 (7.8 to 9.5) B0.01*
]10 32 (19.9) 25 (24.2) 7 (12.1) 0.03**
9 to 10 48 (29.8) 34 (33.0) 14 (24.1)
7 to 9 79 (49.1) 42 (40.8) 37 (63.8)
Missing 2 (1.2) 2 (2.0) 0 (0.0)
Median CD4 percentage at ART initiation (IQR) 19.5 (13.5 to 26.2) 21.5 (15.6 to 28.8) 16.6 (11.0 to 23.5) B0.01*
Immune status at ART initiation 0.58
Normal 21 (13.0) 14 (13.6) 7 (12.1)
Moderate 20 (12.5) 16 (15.5) 4 (6.9)
Advanced 25 (15.5) 15 (14.6) 10 (17.2)
Severe 92 (57.1) 56 (54.4) 36 (62.1)
Missing 3 (1.9) 2 (1.9) 1 (1.7)
Mean viral load at ART initiation (log10) 6.1 (1.1) 5.9 (1.1) 6.5 (0.9) B0.01
Viral load class at ART initiation 0.02
56 log 64 (39.7) 48 (46.6) 16 (27.6)
6 log 95 (59.0) 53 (51.4) 42 (72.4)
Missing 2 (1.3) 2 (2.0) 0 (0.0)
SD: standard deviation; IQR: Interquartile range; ART: antiretroviral therapy; WHO: World Health Organization. Immune status: Age B11
months: normal CD4% 35%, moderate CD4% 535% and ]30%, advanced CD4% 525% and ]29%, severe CD4% B25%; Age ]11 months:
normal CD4% 30%, moderate CD4% 525% and ]30%, advanced CD4% 520% and ]24%, severe CD4% B20%. *p-value from Wilcoxon
rank-sum test; **p-value from Fisher’s exact test; ***WHO 2006 growth standards.
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women do not receive antenatal care. The conditions of
access to prenatal and infant HIV diagnosis and antiretroviral
treatment upstream of the MONOD project were discussed
elsewhere [10]. These results demonstrated the difficulties in
the implementation of PMTCT interventions in West Africa.
The linkage between PMTCT and postnatal care services
needs to be strengthened in order to identify HIV infection
and initiate EART at the earliest opportunity [38]. It is urgent
to raise awareness of both the community and healthcare
workers in order to increase the number of mothers and
children receiving PMTCT and achieve the goal of ‘‘zero new
paediatric infections’’ [39].
Few cases of tuberculosis were identified in our settings
(5/161; 3%), reflecting a difference of contextual morbidity in
West Africa compared to South Africa [40]. Finally, our results
highlight the delayed pre-ART cascade with a low coverage of
EID mentioned in West Africa compared to South Africa [41].
Our study has limitations. First, our data represent only
urban settings, probably reflecting a better access to early
infant diagnosis and antiretroviral treatment compared to
rural settings, where the delay of care could be even longer
than that reported in our study. A few variables presented a
high number of missing data (data on vital status of the
father, his HIV status and antiretroviral treatment, which
were recorded at the pre-inclusion visit). These missing data
were mainly related to children whose parents did not accept
the inclusion in the MONOD project or those who died
before inclusion. Although that selection bias might have
affected the precision of our estimate, we feel that it might
have underestimated the OR estimates. Finally, the need to
get either both parents’ consent (or the mother’s if she was
the only legal guardian, or the legal caregiver if parents were
not alive) before inclusion of the children and EART initiation
in this research context could have also underestimated the
true EART acceptability rate. Those children who did not have
parental consent were included in the ART programme but
not in the research cohort. This may not depict the real life
situation, but this allows us to highlight the place of the
father in the family’s interaction with the field reality and the
mothers’ difficulties of coping with a long-term daily ART
strategy for themselves and their children without the father
knowing it. Despite these limitations, our findings are
original. This is the first study to document the pre-ART
cascade and family acceptability of EART in children less than
two years in the West African context.
Conclusions
Competing early mortality of HIV-infected infants and fear of
stigma within the parental couple play a key role in the
missed opportunities of EART for children in West Africa.
A public health effort must be made in order to take care
of HIV-exposed infants and to identify HIV-infected infants
earlier by strengthening linkages between PMTCT and
paediatric HIV facilities, increasing community awareness
on the need to treat children early, providing a global
package of care for HIV-positive mothers (access to ART,
child nutrition, improvement of socio-economic conditions),
involving the father at the earliest opportunity according
to maternal willingness, facilitating communication within
couples about the disclosure of the child’s HIV status and finally
by fighting against stigma at the community level and among
healthcare workers. These efforts are needed to provide early
HIV care to infants and to improve their survival as efficiently
as shown in the CHER trial [6]. More recently, in 2015,
universal treatment of all HIV-infected patients was recom-
mended by WHO [42]. However children less than two years
old are those with the most advanced stage of the disease,
requiring more rapid initiation of ART compared to older
ones [43]. In the view of the currently enormous unmet need
for paediatric ART provision compared to adults and the 2015
guidelines [42], it is necessary to provide ART for all children,
but also as soon as possible for the youngest children, who
are at a higher risk of death compared to older children.
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